Search company, investor...
Janux Therapeutics company logo

Janux Therapeutics

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Janux Therapeutics

Janux Therapeutics (NASDAQ: JANX) develops T-cell engager bispecifics that combine tumor-specific activation with improved PK.

Headquarters Location

11099 North Torrey Pines Park Road Suite 290

La Jolla, California, 92037,

United States

Missing: Janux Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Janux Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Janux Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Janux Therapeutics is included in 3 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Janux Therapeutics Patents

Janux Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Immunology
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date


Related Topics



Clusters of differentiation, Monoclonal antibodies, Immunology, Immune system, Amino acids


Application Date


Grant Date


Related Topics

Clusters of differentiation, Monoclonal antibodies, Immunology, Immune system, Amino acids



Latest Janux Therapeutics News

Janux Therapeutics to Present at Upcoming Investor Conferences in November

Nov 22, 2022

November 22, 2022 06:00 AM Eastern Standard Time SAN DIEGO--( BUSINESS WIRE )-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings. Details of the presentations are as follows: Piper Sandler 34th Annual Healthcare Conference Date: Tuesday, November 29 Forum: Company Presentation Dates: Wednesday, November 30 Forum: Virtual Fireside Chat About Janux Therapeutics Janux Therapeutics is an innovative clinical-stage biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations by offering accuracy, stability, activity, modularity, and manufacturability. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Janux is also applying its proprietary technology to develop a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and Cluster of Differentiation 28 (CD28) designed to further enhance the anti-tumor activity of T cells. For more information, please visit . Contacts

Janux Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Janux Therapeutics Rank

Janux Therapeutics Frequently Asked Questions (FAQ)

  • When was Janux Therapeutics founded?

    Janux Therapeutics was founded in 2017.

  • Where is Janux Therapeutics's headquarters?

    Janux Therapeutics's headquarters is located at 11099 North Torrey Pines Park Road, La Jolla.

  • What is Janux Therapeutics's latest funding round?

    Janux Therapeutics's latest funding round is IPO.

  • How much did Janux Therapeutics raise?

    Janux Therapeutics raised a total of $192.44M.

  • Who are the investors of Janux Therapeutics?

    Investors of Janux Therapeutics include Avalon Ventures, RA Capital Management, OrbiMed Advisors, Bregua, Janus Henderson Investors and 9 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.